NASDAQ:VSTM Verastem Q2 2026 Earnings Report $6.00 +0.25 (+4.35%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$5.91 -0.09 (-1.52%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Verastem EPS ResultsActual EPSN/AConsensus EPS -$0.46Beat/MissN/AOne Year Ago EPSN/AVerastem Revenue ResultsActual RevenueN/AExpected Revenue$22.88 millionBeat/MissN/AYoY Revenue GrowthN/AVerastem Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Verastem Earnings HeadlinesVerastem’s KRAS G12D Trial Targets a New Niche in Colorectal CancerJuly 17, 2026 | tipranks.comRBC Capital Reaffirms Outperform Rating For Verastem (VSTM)July 16, 2026 | finance.yahoo.comBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.July 22 at 1:00 AM | Awesomely (Ad)RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)July 15, 2026 | insidermonkey.comVerastem Updates Strategy for RAS/MAPK Oncology PipelineJuly 7, 2026 | theglobeandmail.comHere’s What RBC Capital Has to Say About Verastem (VSTM)July 3, 2026 | insidermonkey.comSee More Verastem Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Verastem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verastem and other key companies, straight to your email. Email Address About VerastemVerastem (NASDAQ:VSTM) Oncology, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept. The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S. Food and Drug Administration approval in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma. In parallel, Verastem Oncology has built a differentiated pipeline of targeted therapies, including selective Rho/MRTF pathway inhibitors and focal adhesion kinase (FAK) inhibitors, which are being evaluated in various solid tumor and blood cancer settings. Ongoing clinical trials are designed to explore monotherapy activity as well as combination regimens that may overcome resistance and improve patient outcomes. Verastem Oncology conducts its clinical and translational research activities primarily in the United States, with strategic partnerships and investigator-initiated studies extending into Europe. The company collaborates with academic institutions and industry partners to accelerate the development of its pipeline assets. Verastem Oncology’s leadership team comprises experienced drug developers and oncology specialists who are committed to advancing novel therapies that address unmet medical needs in cancer treatment. View Verastem ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity? Upcoming Earnings RTX (7/23/2026)Lockheed Martin (7/23/2026)Newmont (7/23/2026)Intel (7/23/2026)Nokia (7/23/2026)Relx (7/23/2026)SAP (7/23/2026)STMicroelectronics (7/23/2026)T-Mobile US (7/23/2026)Comfort Systems USA (7/23/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
